Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

Phase 2 Terminated 25 enrolled Asociación para Evitar la Ceguera en México

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

Timeline

Start: 2006-03
Primary completion: 2006-06-30
Completion: 2007-06-30

Outcome

Outcome not reported

Stopped: “undefined”

Publications

Background Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	2.5 mg	Intravitreal